Ginkgo Bioworks Holdings (DNA) said Thursday the Advanced Research Projects Agency for Health has awarded the company and its partners a $29 million contract for a project to stabilize and reshore supply chains for essential pharmaceuticals.
The company and its partners, Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals and Isolere Bio by Donaldson, will use wheat germ cell-free expression systems to develop distributed manufacturing of essential medicines under the two-year program, Ginkgo Bioworks said.
The strategy moves the production of active pharmaceutical ingredients to a "robust" and decentralized system from "fragile" global supply chains, the company said.
Price: 6.56, Change: -0.23, Percent Change: -3.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。